Berenberg Bank analyst Ravi Misra maintained a Buy rating on Avanos Medical (NYSE:AVNS) on Wednesday, setting a price target of $45, which is approximately 28.50% above the present share price of $35.02.
Misra expects Avanos Medical to post earnings per share (EPS) of $0.79 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Hold rating of shares in Avanos Medical, with an average price target of $40.67.
The analysts price targets range from a high of $45 to a low of $37.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $186.4 million and a net profit of -$7.3 million. The company's market cap is $1.69 billion.
According to TipRanks.com, Berenberg Bank analyst Ravi Misra is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.5% and a 56.25% success rate.
Avanos Medical, Inc. is a medical technology company, which focuses on delivering clinically medical device solutions to improve patients' quality of life. Its portfolio of innovative product offerings focused on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.